Exact Sciences (EXAS) Set to Announce Quarterly Earnings on Tuesday

Exact Sciences (NASDAQ:EXAS) is scheduled to announce its earnings results after the market closes on Tuesday, November 5th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Wednesday, July 31st. The medical research company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.28. The firm had revenue of $699.26 million for the quarter, compared to the consensus estimate of $690.02 million. Exact Sciences had a negative net margin of 6.70% and a negative return on equity of 4.97%. The firm’s revenue was up 12.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.45) earnings per share. On average, analysts expect Exact Sciences to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Exact Sciences Stock Up 0.3 %

EXAS stock opened at $69.35 on Tuesday. The company has a current ratio of 2.17, a quick ratio of 1.98 and a debt-to-equity ratio of 0.73. The company has a market cap of $12.80 billion, a P/E ratio of -52.54 and a beta of 1.27. The company’s 50-day moving average price is $65.98 and its 200 day moving average price is $56.43. Exact Sciences has a 52 week low of $40.62 and a 52 week high of $79.62.

Insider Buying and Selling

In related news, EVP Brian Baranick sold 929 shares of the company’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $70.00, for a total transaction of $65,030.00. Following the completion of the transaction, the executive vice president now owns 13,687 shares of the company’s stock, valued at approximately $958,090. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.36% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on EXAS. Evercore ISI lifted their target price on shares of Exact Sciences from $72.00 to $80.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Canaccord Genuity Group restated a “buy” rating and set a $75.00 target price on shares of Exact Sciences in a research report on Friday, September 13th. Raymond James restated a “market perform” rating on shares of Exact Sciences in a research report on Thursday, September 26th. Benchmark cut their target price on shares of Exact Sciences from $91.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. Finally, Stifel Nicolaus cut their target price on shares of Exact Sciences from $100.00 to $82.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $78.38.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.